|
2005/04/16, 03:33 PM
just as an aside, carnitine supplements arent going to do much for if you are a normal healthy person, its for those who are deficient in producing it. Carnitine acts as a transporter for getting fatty acyl-CoA from the cytosol of a cell into the mitochondrial matrix by the enzyme carnitine palmitoyl transferase (CPT). oral ingestion of carnitine supplements do not make it to this level of the muscle, yielding it pretty much useless.
if i were you, i would bring it back unless you are sure you are carnitine deficient. otherwise, its just a waste of money..
|
|
2005/04/16, 05:07 PM
I would opt for ALCAR. Read on....
ALCAR improves both Short-Term Memory and Long-Term Memory.
ALCAR improves Mood .
Acetyl L-Carnitine retards some aspects of the Aging Process in the Skin:
ALCAR improves the reaction times of people afflicted with Cerebral Insufficiency.
ALCAR (2-4 grams per day) improves walking distance without Pain in people afflicted with Intermittent Claudication. (click here to return to the ALCAR order page)
ALCAR prevents the age-related impairment of Eyesight (by protecting the Neurons of the Optic Nerve and the Occipital Cortex of the Brain.
ALCAR enhances the ability of Macrophages to function as Phagocytes.
ALCAR improves Athletic Performance .
ALCAR enhances the function of Cytochrome Oxidase (an essential enzyme of the Electron Transport System (ETS).
ALCAR improves the Energy metabolism of Neurons (by enhancing the transport of Medium-Chain Saturated Fatty Acids and Short-Chain Saturated Fatty Acids across the Cell Membranes of Neurons into the Mitochondria).
ALCAR inhibits the damage caused by Hypoxia.
ALCAR transports Lipids into the Mitochondria of Cells.
ALCAR improves mood and memory in people with Age Associated Memory Impairment.
ALCAR improves Mental Function where ALCARohol induced cognitive Impairment exists.
ALCAR increases Alertness.(click here to order ALCAR)
Acetyl-L-Carnitine inhibits the deterioration in Mental Function associated with Alzheimer’s Disease and slows the progression of Alzheimer’s Disease .
ALCAR increases Alertness in people afflicted with Alzheimer's Disease - 2,500-3,000 mg per day for 3 months].
ALCAR inhibits the toxicity of Amyloid-Beta Protein (ABP) to Neurons.
ALCAR improves Attention Span in people afflicted with Alzheimer's Disease.
ALCAR improves Short Term Memory in people afflicted with Alzheimer's Disease.
High concentrations of ALCAR are naturally present in various regions of the Brain.
ALCAR reverses the age-related decline that occurs in Cholinergic Receptors (i.e. the Receptors that receive Acetylcholine).
ALCAR improves (eye to hand) Coordination .
ALCAR improves the Interhemispheric Flow of Information across the Corpus Callosum of the Brain.
ALCAR retards the decline in the number of Dopamine Receptors that occurs in tandem with the Aging Process and (more rapidly) with the onset of Parkinson's Disease.
ALCAR enhances the release of Dopamine from Dopaminergic Neurons and improves the binding of Dopamine to Dopamine Receptors.
ALCAR can prevent the destruction of Dopamine Receptors by MPTP (a neurotoxin capable of causing Parkinson's Disease via Dopaminergic Receptor death.
ALCAR improves Attention Span and Memory in people afflicted with Down’s Syndrome.
ALCAR retards the inevitable decline in the number of Glucocorticoid Receptors that occurs in tandem with the Aging Process.
ALCAR enhances the recovery of people afflicted with Hemiplegia (Paralysis of one side of the body) and improves their Mood and Attention Span.
ALCAR retards the age-related deterioration of the Hippocampus .
Acetyl-L-Carnitine (ALCAR) improves Learning ability .
ALCAR inhibits (and possibly reverses) the degeneration of Myelin Sheaths that occurs in tandem with the progression of the Aging Process .
ALCAR retards the inevitable decline in the number of Nerve Growth Factor (NGF) Receptors that occurs in tandem with the Aging Process.
ALCAR stimulates and maintains the growth of new Neurons within the Brain (both independently of Nerve Growth Factor (NGF) and as a result of preserving NGF) and helps to prevent the death of existing Neurons .
ALCAR inhibits the degeneration of Neurons that is implicit in Neuropathy.
ALCAR rejuvenates and increases the number of N-Methyl-D-Aspartate Receptors (NMDA Receptors) in the Brain :
ALCAR protects the NMDA Receptors in the Brain from the natural decline that occurs in tandem with the Aging Process .
ALCAR is presently being researched as a treatment for Parkinson's Disease.
ALCAR inhibits the loss of Vision, degeneration of Neurons and damage to the Retina associated with Retinopathy (including Diabetic Retinopathy).
ALCAR improves the quality of Sleep and reduces the quantity of Sleep required.
ALCAR improves Spatial Memory (an aspect of Short Term Memory that involves remembering one’s position in space).
ALCAR inhibits the excessive release of Cortisol in response to Stress and inhibits the depletion of Luteinising Hormone Releasing Hormone (LHRH) and Testosterone that occurs as a result of excessive Stress.
ALCAR improves Verbal Fluency.
ALCAR enhances the function of Cytochrome Oxidase (also called Complex IV) - an essential enzyme of the Electron Transport System.
ALCAR normalizes Beta-Endorphin levels.
ALCAR reduces Stress-induced Cortisol release .
ALCAR prevents the depletion of Luteinising Hormone Releasing Hormone (LHRH) caused by exposure to excessive Stress.
ALCAR retards the decline in the production of Nerve Growth Factor (NGF) that occurs in tandem with the Aging Process.
ALCAR increases plasma Testosterone levels (via its influence on Acetylcholine neurotransmission in the Striatal Cortex of the Brain) and prevents the depletion of Testosterone caused by exposure to excessive Stress .
ALCAR increases the body's levels of circulating Thyrotrophin.
ALCAR facilitates the production of Adenosine Triphosphate (ATP) .
ALCAR "shuttles" Long Chain Fatty Acids between the Cytosol and the Mitochondria of Cells.
ALCAR facilitates both the release and synthesis of Acetylcholine.
ALCAR's ability to increase the synthesis of Acetylcholine occurs as a result of it donating its Acetyl group towards the production of Acetylcholine.
ALCAR increases the Brain's levels of Choline Acetylase (which in turn facilities the production of Acetylcholine).
ALCAR enhances the release of Dopamine from Dopaminergic Neurons and improves the binding of Dopamine to Dopamine Receptors. (click here to return to the ALCAR order page)
References:
De FALCARo, F. A., et al. Effect of the chronic treatment with L-acetylcarnitine in Down’s syndrome. Clin Ther. 144:123-127, 1994.
Bowman, B. Acetyl-carnitine and Alzheimer’s disease. Nutr Rev. 50:142-144, 1992.
Bruno, G., et al. Acetyl-L-carnitine in Alzheimer disease: a short-term study on CSF neurotransmitters and neuropeptides. Alzheimer Dis Assoc Disord (USA). 9(3):128-131, 1995.
Calvani, M., et al. Action of acetyl-L-carnitine in neurodegeneration and Alzheimer’s disease. Annals of the New York Academy of Sciences (USA). 663:483-486, 1993.
Carta, A., et al. Acetyl-L-carnitine: a drug able to slow the progress of Alzheimer’s Disease? Annals of the New York Academy of Sciences (USA. 640:228-232, 1991.
Guarnaschelli, C., et al. Pathological brain ageing: evaluation of the efficacy of a pharmacological aid. Drugs under Experimental and Clinical Research. 14(11):715-718, 1988.
Passeri, M., et al. Acetyl-L-carnitine in the treatment of mildly demented elderly patients. International Journal of Clinical Pharmacology Research. 10(1-2):75-79, 1990.
Pettegrew, J. W., et al. Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer’s disease. Neurobiol Aging. 16:1-4, 1995.
Rai, G., et al. Double-blind, placebo controlled study of acetyl-L-carnitine in patients with Alzheimer’s dementia. Current Medical Research and Opinion. 11(10):638-647, 1989.
Sano, M., et al. Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer’s disease. Arch Neurol. 49:1137-1141, 1992.
Sinforiani, E., et al. Neuropsychological changes in demented patients treated with acetyl-L-carnitine. International Journal of Clinical Pharmacology Research. 10(1-2):69-74, 1990.
Spagnoli, A. U., et al. Long-term acetyl-l-carnitine treatment in Alzheimer’s disease. Neurology. 41(11):1726-1732, 1991.
*This information based on smart-drugs.net
--------------
If you don't stand for something, you will fall for anything....
bb1fit@freetrainers.com
|
